Bioporto AS (OCSE:BIOPOR) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


OCSE:BIOPOR Bioporto AS OCSE:BIOPOR
66 GF Score
Price kr1.11
GF Value kr1.24
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bioporto AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bioporto AS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OCSE:BIOPOR vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Bioporto AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioporto AS Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Bioporto AS's Margin of Safety % (DCF Earnings Based) falls into.


OCSE:BIOPOR
66GF Score
Bioporto AS OCSE:BIOPOR
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of kr1.11 is trading 10.9% below its estimated GF Value™ of kr1.24. GuruFocus considers Bioporto AS to be Modestly Undervalued.

Key valuation signals for OCSE:BIOPOR:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr1.24 vs. price of kr1.11 (10.9% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score

Get the complete analysis for OCSE:BIOPOR

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.11
Price
kr1.24
GF Value